Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases

Emergex Vaccines Holding Limited announced that it has raised $11 million in a funding round supported by new and existing investors.The proceeds of this funding round will enable Emergex to further advance and execute its vaccine development strategy, producing vaccine candidates for some of the world’s most threatening and virulent diseases such as COVID-19, Dengue Fever and pandemic flu.